Skip to main content
logo
Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
56.45
-0.65 (-1.13%)
Jun 30, 2026, 1:49 PM EDT - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Cystic Fibrosis Franchise Revenue
845.05M828.18M826.21M
Cystic Fibrosis Franchise Revenue Growth
2.04%0.24%-3.06%
Evrysdi Revenue
210.91M206.97M224.43M
Evrysdi Revenue Growth
1.90%-7.78%129.61%
Trelegy Revenue
158.40M154.10M146.92M
Trelegy Revenue Growth
2.79%4.89%14.74%
Tremfya Revenue
161.50M152.94M147.14M
Tremfya Revenue Growth
5.60%3.94%-1.72%
Voranigo Revenue
167.68M154.42M46.15M
Voranigo Revenue Growth
8.59%234.58%-
Tysabri Revenue
112.52M116.88M124.82M
Tysabri Revenue Growth
-3.73%-6.36%-25.50%
Other Products Revenue
660.60M647.67M633.76M
Other Products Revenue Growth
2.00%2.20%0.72%
Total Income from Financial Royalty Assets
2.32B2.26B2.15B
Total Income from Financial Royalty Assets Growth
2.46%5.20%-2.20%
Other Royalty Income and Revenue
123.87M117.04M114.15M
Other Royalty Income and Revenue Growth
5.83%2.53%-27.20%
Revenue (Other)
-167.68M-154.42M-46.15M
Revenue (Total)
2.44B2.38B2.26B
Revenue (Total) Growth
2.62%5.06%-3.86%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Portfolio Receipts
3.34B3.25B2.80B
Portfolio Receipts Growth
2.65%16.17%-8.11%